Publications by authors named "Ed Parsley"

Claim this Profile
S
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study.
Olivier Sitbon, Sandeep Sahay, Pilar Escribano Subías, Ronald L Zolty, John F Kingrey, Ed Parsley

Adv Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug-Drug Interactions in Healthy Participants.
Jianke Li, Ed Parsley, Matt Cravets, Emanuel DeNoia, Cassandra Key

Clin Pharmacol Drug Dev· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial.
Olivier Sitbon, Andris Skride, Jeremy Feldman, Sandeep Sahay, Oksana A Shlobin, Ed Parsley

Lancet Respir Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Robert P Frantz, Vallerie V McLaughlin, Sandeep Sahay, Pilar Escribano Subías, Ronald L Zolty, Ed Parsley

Lancet Respir Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.
Christopher S King, Kevin R Flaherty, Marilyn K Glassberg, Lisa Lancaster, Ganesh Raghu, Ed Parsley

Ann Am Thorac Soc· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects.
Robert F Roscigno, Toby Vaughn, Ed Parsley, Thomas Hunt, Michael A Eldon

Vascul Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
James F Casella, Bruce A Barton, Julie Kanter, L Vandy Black, Suvankar Majumdar, Ed Parsley

JAMA· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction.
Marc A Simon, Rebecca R Vanderpool, Mehdi Nouraie, Timothy N Bachman, Pamela M White, Ed L Parsley

JCI Insight· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, safety, and tolerability of nebulized sodium nitrite (AIR001) following repeat-dose inhalation in healthy subjects.
Peter J Rix, Andrew Vick, Neil J Attkins, Geoffrey E Barker, Adrian W Bott, Ed L Parsley

Clin Pharmacokinet· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 26-Week Toxicity Assessment of AIR001 (Sodium Nitrite) by Inhalation Exposure in Rats and by Intravenous Administration in Dogs.
Jeffrey Tepper, Ricardo Ochoa, Peter Rix, Gary Elliott, Niel Hoglen, Ed Parsley

Int J Toxicol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Michael D Roth, Daniel E Furst, Ed Parsley

Am J Respir Crit Care Med· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Dinesh Khanna, Xiaohong Yan, Donald P Tashkin, Daniel E Furst, Robert Elashoff, Ed Parsley

Arthritis Rheum· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Jonathan Goldin, Michael D Roth, Ed Parsley

N Engl J Med· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes.
Raymond F Hamilton, Ed Parsley, Andrij Holian

Am J Physiol Lung Cell Mol Physiol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis